Microvascular Therapeutics Licenses Patents from Stanford University
Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, has licensed two patent applications from Stanford University to support the development for detection of pancreatic cancer.
Tucson, AZ, April 16, 2019 --(PR.com)-- Microvascular Therapeutics, LLC (www.mvtpharma.com)
Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, has licensed two patent applications from Stanford University, US Patent Application No. 62/347,345, entitled “Detection of Pancreatic Cancer with an Engineered Anti-Thy-1 Single Chain Antibody” filed on August 6th, 2016 and US Patent Application No. 15/951,567 entitled “Methods and Compositions for Cancer Diagnosis” filed on April 12th, 2018. Wyatt Unger, MD, MBA, President and CEO of MVT said, “We are excited about licensing these two patent applications. Pancreatic cancer is a deadly disease, usually detected after the cancer has spread and is no longer curable. We have developed a new ultrasound contrast agent which enables detection of tumors less than 3-mm in size in preclinical models. With the technology licensed, we aim to develop a molecularly targeted ultrasound contrast agent to detect early stage pancreatic cancer while it is still curable.”
The founders of MVT previously developed Definity®, the worlds #1 selling ultrasound contrast agent which is FDA approved for echocardiography (imaging the heart). MVT has developed a new, improved ultrasound contrast agent, MVT-100, which is currently in clinical testing and is being supported by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. MVT is modifying the MVT-100 microbubble for pancreatic cancer detection by incorporating a single chain antibody into the microbubbles for a biomarker expressed in pancreatic cancer.
The American Cancer Society's estimates for pancreatic cancer in the United States for 2019 are: About 56,770 people (29,940 men and 26,830 women) will be diagnosed with pancreatic cancer. About 45,750 people (23,800 men and 21,950 women) will die of pancreatic cancer. The 5-year relative survival rate for localized disease is 34% while dropping down to 3% if the disease has spread throughout the body. The latter population represents 52% of pancreatic cancer patients. Thus, early detection is an immediate and urgent need for these patients and could save lives.
About Microvascular Therapeutics (MVT)
Microvascular Therapeutics is a biotechnology company based in Tucson, Arizona and is a leader in microbubble technology. MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease. The chemists at MVT have developed a new, patented formulation that may potentially serve as a platform for development of agents for molecular imaging and image-guided therapy. (www.mvtpharma.com)
For further information contact Wyatt Unger at w.unger@mvtpharma.com
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Microvascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, has licensed two patent applications from Stanford University, US Patent Application No. 62/347,345, entitled “Detection of Pancreatic Cancer with an Engineered Anti-Thy-1 Single Chain Antibody” filed on August 6th, 2016 and US Patent Application No. 15/951,567 entitled “Methods and Compositions for Cancer Diagnosis” filed on April 12th, 2018. Wyatt Unger, MD, MBA, President and CEO of MVT said, “We are excited about licensing these two patent applications. Pancreatic cancer is a deadly disease, usually detected after the cancer has spread and is no longer curable. We have developed a new ultrasound contrast agent which enables detection of tumors less than 3-mm in size in preclinical models. With the technology licensed, we aim to develop a molecularly targeted ultrasound contrast agent to detect early stage pancreatic cancer while it is still curable.”
The founders of MVT previously developed Definity®, the worlds #1 selling ultrasound contrast agent which is FDA approved for echocardiography (imaging the heart). MVT has developed a new, improved ultrasound contrast agent, MVT-100, which is currently in clinical testing and is being supported by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. MVT is modifying the MVT-100 microbubble for pancreatic cancer detection by incorporating a single chain antibody into the microbubbles for a biomarker expressed in pancreatic cancer.
The American Cancer Society's estimates for pancreatic cancer in the United States for 2019 are: About 56,770 people (29,940 men and 26,830 women) will be diagnosed with pancreatic cancer. About 45,750 people (23,800 men and 21,950 women) will die of pancreatic cancer. The 5-year relative survival rate for localized disease is 34% while dropping down to 3% if the disease has spread throughout the body. The latter population represents 52% of pancreatic cancer patients. Thus, early detection is an immediate and urgent need for these patients and could save lives.
About Microvascular Therapeutics (MVT)
Microvascular Therapeutics is a biotechnology company based in Tucson, Arizona and is a leader in microbubble technology. MVT’s mission is to develop the next generation of contrast agents for diagnostic ultrasound and advance the field of ultrasound for diagnosis and treatment of disease. The chemists at MVT have developed a new, patented formulation that may potentially serve as a platform for development of agents for molecular imaging and image-guided therapy. (www.mvtpharma.com)
For further information contact Wyatt Unger at w.unger@mvtpharma.com
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” Actual events or results may differ substantially as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Contact
MicroVascular Therapeutics LLC
Jennifer Marshall
520-624-6688
mvtpharma.com
Jennifer Marshall
520-624-6688
mvtpharma.com
Contact
Categories